503b bulk list
Hidden Cost of FDA Excluding Semaglutide From Bulk
In 2026 the FDA removed semaglutide, tirzepatide and liraglutide from the 503B bulk list, a shift that threatens over 1,200 accredited compounding pharmacies with higher drug prices and lost revenue. The rule redirects responsibility for these high-profile weight-loss therapies to traditional manufacturers, leaving labs to reassess their supply strategies.